anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ENHANCE (Enduring Happiness and Continued Self-Enhancement) is a 12-week program that includes an introductory session, 10 weekly sessions focusing on different happiness principles, and a final session focusing on integrating aspects of the program and continuing to practice these principles moving forward. Through completing this program, participants will gain an education on a wide-range of happiness principles and an arsenal of strategies for developing happiness boosting habits and skills.
Drug: Tadalafil + placebo injection Patients will be treated by tadalafil 5 mg tablet daily in addition to four Tadalafil 5 mg tablet 3 hours before intercourse on demand in addition to placebo injection. Each injection session will consist of a total of 10 mL saline solution infused slowly over a 2-minute period; 5 mL each injected to the right and left corpus cavernosum.
Participants received interferon alfa-2b (Intron\^® A), recombinant for injection, at a dose of 5 million international units (MIU)/m\^2, administered daily by SC injection. Participants may have received hydroxyurea therapy as needed prior to randomization to reduce or keep the WBC count ≤50,000/μl. Treatment was for a minimum of 6 months unless there was evidence of disease progression or unacceptable toxicity.
Physicians should instruct patients on the appropriate administration of tadalafil tablets to allow optimal use.

For tadalafil tablets for use as needed in men with ED, patients should be instructed to take one tablet at least 30 minutes before anticipated sexual activity. In most patients, the ability to have sexual intercourse is improved for up to 36 hours.

For tadalafil tablets for once daily use in men with ED or ED/BPH, patients should be instructed to take one tablet at approximately the same time every day without regard for the timing of sexual activity. Tadalafil tablets are effective at improving erectile function over the course of therapy.

For tadalafil tablets for once daily use in men with BPH, patients should be instructed to take one tablet at approximately the same time every day.
Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive JNJ-70218902. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.
Provided herein are components for antigen binding constructs, including antibodies and fragments thereof, such as minibodies and cys-diabodies, that bind to a target molecule, for example, DLL3. In some embodiments, these components are novel complementarity-determining region (CDR) sequences and/or sequences associated with and/or part of the CDR sequence. In some embodiments, these components are novel framework region (FR) sequences and/or sequences associated with and/or part of the FR sequence. These CDR and FR sequences can provide various benefits. Also provided herein are the antigen binding constructs (such as, minibodies, cys-diabodies, etc.) that include one or more of the CDR or FR sequences or subsequences provided herein.
Preparing a topical composition from mother of pearl, is new. Preparing a topical composition comprises: (a) reducing a mother of pearl to a powder having a particle size of 1- 300 micro m, especially 15 - 50 micro m; (b) contacting the powder with an extraction agent which is an aqueous glycolic solution of a collagen and one or more proteoglycans; and (c) the mixture is recovered. Optionally this may be then be separated into a solid and a liquid phase. The weight ratio of water:glycol used may vary between 1:100 and 100:1. Marine collagen is preferably used, the commercial products Pancogene Marin  (RTM) or Collagen Natif Marin - Code 690 (RTM) being preferred. Amounts of collagen in the range of 0.0001 - 50 % are used. The proteoglycan used may be hyaluronic acid, chondroitin sulfate, dermatane sulfate, eperane sulfate, keratane sulfate and their mixtures. Solutions containing 0.0001 - 40 % hyaluronic acid are preferred. The product contains aragonite, trace elements (Na, Mg, La, Zn, Br, Cs, Fe, Mn, Cl, Cu, K, Ca, Sr, S), fibrous proteins, non-fibrous proteins, and collagens and/or proteoglycans that have not derived from the mother of pearl. Independent claims are also included for the following:  (1) compositions made by the new process; and (2) use of the compositions for dermatological or cosmetic uses.
All three interventions will be provided in a randomized double-blind order. The interventions will consist of 8 grams per day of three different types of powdered food supplement that will be mixed with water and consumed for a 7-day period. The powdered food supplement will be either placebo (glucose), fibre 1 (derived from a plant-based food) or fibre 2 (derived from a different plant-based food).
Participants in this arm will receive a text message from a call center agent if they press "1" in response to a question on the original text message. The bidirectional texts will have an agent who can answer questions and schedule an appointment through text message back-and-forth conversations with the patient. Bidirectional texts will be exchanged on a HIPAA compliant bidirectional text messaging platform. The patient will use the regular SMS function on their cellphone and the agent will receive and respond to the bidirectional text on the HIPAA compliant platform.
PURPOSE: A skin regeneration promoting agent containing epidermal growth factor(EGF), platelet-derived growth factor-AA(PDGF-AA), and insulin-like growth factor 1(IGF-1) is provided to promote skin regeneration and wound healing, and to minimize scar. CONSTITUTION: A skin regeneration promoting agent contains EGF, PDGF-AA, and IGF-1. The skin regeneration promoting agent further contains one or more growth factors among TGF(transforming growth factor beta) and FGF(fibroblast growth factor). The skin regeneration promoting agent promotes wound healing and regeneration of keratinocyte or fibroblast. A cosmetic composition or a pharmaceutical composition contains the skin regeneration promoting agent. [Reference numerals] (AA) Wound fill percentage(%); (BB) Control group
Serious drug-induced liver injury (DILI), including liver transplantation and death, have been reported postmarketing with TRICOR. DILI has been reported within the first few weeks of treatment or after several months of therapy and in some cases has reversed with discontinuation of TRICOR treatment. Patients with DILI have experienced signs and symptoms including dark urine, abnormal stool, jaundice, malaise, abdominal pain, myalgia, weight loss, pruritus, and nausea. Many patients had concurrent elevations of total bilirubin, serum alanine transaminase (ALT), and aspartate transaminase (AST). DILI has been characterized as hepatocellular, chronic active, and cholestatic hepatitis, and cirrhosis has occurred in association with chronic active hepatitis.

In clinical trials, fenofibrate at doses equivalent to 96 mg to 145 mg TRICOR daily has been associated with increases in serum AST or ALT. The incidence of increases in transaminases may be dose related [see Adverse Reactions (6.1)]. 

TRICOR is contraindicated in patients with active liver disease, including those with primary biliary cirrhosis and unexplained persistent liver function abnormalities [see Contraindications (4)]. Monitor patient’s liver function, including serum ALT, AST, and total bilirubin, at baseline and periodically for the duration of therapy with TRICOR. Discontinue TRICOR if signs or symptoms of liver injury develop or if elevated enzyme levels persist (ALT or AST > 3 times the upper limit of normal, or if accompanied by elevation of bilirubin). Do not restart TRICOR in these patients if there is no alternative explanation for the liver injury.
BACKGROUND: This study aimed to characterize the urinary and tumor microbiomes in patients with non-muscle-invasive bladder cancer (NMIBC) before and after transurethral resection of the bladder tumor (TURBT).
METHODS: This single-center prospective study included 26 samples from 11 patients with low-grade Ta papillary NMIBC. Urine samples were collected at the index TURBT and at a 1-year follow-up cystoscopy. The metagenomic analysis of bacterial and archaeal populations was performed based on the highly variable V3-V4 region of the 16S rRNA gene.
RESULTS: Phylogenetic alpha diversity of the bladder microbiome detected in urine was found to be lower at the 1-year follow-up cystoscopy compared to the time of the index TURBT (p < 0.01). Actinomyces, Candidatus cloacimonas, Sphingobacterium, Sellimonas, Fusobacterium, and Roseobacter were more differentially enriched taxa in urine at the follow-up cystoscopy than at the index TURBT. Beta diversity of urine microbiome significantly changed over time (p < 0.05). Phylogenetic alpha diversity of the microbiome was greater in tumor tissues than in paired urine samples (p<0.01). Sphingomonas, Acinetobacter, Candidatus, and Kocuria were more differentially overrepresented in tumor tissues than in urine. The enrichment of the abundance of Corynebacterium and Anaerococcus species in urine collected at TURBT was observed in patients who experienced recurrence within the follow-up period.
CONCLUSIONS: In patients with low-grade NMIBC, the urine microbiome undergoes changes over time after removal of the tumor. The microbiome detected in tumor tissues is more phylogenetically diverse than in paired urine samples collected at TURBT. The interplay between bladder microbiome, tumor microbiome, and their alterations requires further studies to elucidate their predictive value and perhaps therapeutic implications.
The invention discloses a recombinant vaccine of ApoB100 yeast as well as a preparation method and application thereof. The recombinant vaccine of the yeast takes yeast as a host cell and transfects an eukaryotic expression vector of an ApoB100 gene segment. The nucleotide sequence of the ApoB100 gene segment is as shown in SEQ. ID. NO. 1. The eukaryotic expression vector is JMB88-HA-OVA-hApoB100. The recombinant vaccine of the yeast is fed by an oral manner, can be induced by copper sulfate in the yeast to express an OVA-hApoB fusion protein and split and released in vivo to lead to integrated body fluid and cellular immune response through antigen presentation so as to realize the purpose of relieving and treating atherosclerosis. The recombinant vaccine can be applied to preparing medicines for treating atherosclerosis.
Transbronchial biopsies (BPTB) will be performed using a flexible bronchoscope and the biopsy will be performed with cryoprobe (Erbokryo®). The patient undergoing the procedure will be intubated, sedated and relaxed under continuous monitoring (pulse oximetry, blood pressure, heart and respiratory rate), oxygen therapy with high flows and surveillance by anesthesiologist. The site where the biopsies will be performed will be determined based on an imaging study (chest x-ray and / or CT scan). The procedure will be performed according to the conventional technique, keeping the patient in apnea during the time that the cryobiopsies are taken to reduce the risk of pneumothorax. At most 6 samples will be obtained, and each one will be placed in an individual container listed in order of extraction. Bronchoalveolar lavage (3 aliquots of 30 mL sterile saline solution) will be performed in the same hemithorax. The samples obtained will be evaluated morphologically and sent to a microbiological and histopathological study, which will include a cell count. The data obtained will be coded.
Schizophrenia remains one of the most disabling conditions world-wide with an economic burden that exceeded $155 billion dollars in fiscal year 2013 alone. Despite existing medication and community treatment, many individuals with this diagnosis continue to have poor outcomes and struggle toward recovery. CAT is a psychosocial treatment using environmental supports such as signs, alarms, pill containers, checklists, technology and the organization of belongings established in a person's home or work environment to bypass the cognitive and motivational difficulties associated with schizophrenia, and support habits for functional behavior to promote recovery. In a series of efficacy studies, CAT improved social and occupational functioning, symptoms, and adherence to medication, and reduced rates of readmission. The investigators propose a cluster randomized effectiveness trial comparing Cognitive Adaptation Training (CAT) to existing community treatment (CT) for individuals with schizophrenia in 8 community mental health centers across multiple states including 400 participants. This would be the first large-scale effectiveness study of CAT for improving functional outcomes for those with schizophrenia seen in community mental health centers (CMHCs) where the majority of those with schizophrenia are followed for outpatient care and to study the purported mechanisms of action based on an integrated theoretical model. Participants will be assessed at baseline and 6 and 12 months on measures of functional and community outcome, medication adherence, symptoms, habit formation and automaticity, cognition and motivation. CAT treatment will be weekly for 6 months, biweekly for 3 months and monthly for the remainder of the trial. Purported mechanisms of action for CAT including bypassing impairments in cognitive function to improve functional outcome and bypassing motivational impairments to create automatic habits to improve functional outcome will be examined.
FIELD: medicine. SUBSTANCE: composition contains, mg: cation-exchange resin containing bivalent iron 20-60, cation-exchange resin in cobalt form having cobalt content 2-6, ascorbic acid 25-75. Above mentioned cation-exchange resin in iron and cobalt form is used as source of iron and cobalt ions. Thus absorption and assimilation of iron ions in the presence of ascorbic acid is improved; due to prolonged simultaneously adding iron and cobalt ions hemopoiesis is increased. EFFECT: increases antianemia effect, decreases by-effects. 2 tbl
The invention relates to the field of genetic engineering, and in particular relates to an anti-EGFR ((Epidermal Growth Factor Receptor) chimeric antigen receptor, and a lymphocyte for expressing the antigen receptor. The technical solution of the invention provides a new effective selection for the anti-tumor technical field. The technical scheme is that a single-chain antibody targeting the EGFR is provided. The single-chain antibody is further designed to be constructed into the chimeric antigen receptor by means of a genetic engineering technology, and the structure of the gained chimeric antigen receptor is anti-EGFR (scFv)-IgG2 (Fc)-CD28-CD3 Zeta. According to the genetically engineered lymphocyte targeting the human EGFR, the chimeric antigen receptor is transfected into the lymphocyte by the nucleofaction technology, and thus the nonspecific lymphocyte can be endowed with the capacity of specifically distinguishing the EGFR tumor antigen and targeting and killing the EGFR over-expression tumor cells. According to the technical scheme, the adoptive cell therapy and the genetic therapy are organically combined, so that remarkable effect of killing the tumor is gained, and a novel effective selection is provided for the field.
In the group consisting of healthy volunteers, which will be taken to determine the normative values of the outcome measurements for diaphragmatic tissue Doppler imaging and ultrasonographic evaluation, 2 sessions a day with a threshold-loaded inspiratory muscle training device, starting at 30% of the MIP value, 5 days a week for 4 weeks. Inspiratory muscle training will be performed in 4 sets, 6-8 breaths in each set and 2 minutes rest between sets. In the second evaluation to be made after the inspiratory muscle training, the above-mentioned evaluations and measurements will be repeated.
The pelvic floor requires an integrated anatomical structure owing to its multiple functions. Therefore, it is necessary to study methods for improving muscle recruitment during training. This study aimed to analyze the effect of using an innovative vaginal trainer on the bioelectrical activity of the pelvic floor muscles. Pelvic positioning and interference factors, such as age, childbirth, sexual activity, urinary incontinence, and menopause, were also analyzed. A cross-sectional study assessed 30 women using an evaluation form, International Consultation on Incontinence Questionnaire-Short Form, and surface electromyography. The root mean square of a 5-second contraction period, peak root mean square values, area values, % maximal voluntary contraction (root mean square normalized by peak signal), and median frequency were collected. These findings with and without the use of a vaginal educator were compared in the anteversion, neutral, and retroversion pelvic positions. The use of a vaginal educator was found to increase the electromyographic activity of the pelvic floor muscles in the neutral position. In this position, older women showed an increased peak contraction when using the educator. Multiparas also benefited from increased bioelectric activity (root mean square and area). Sexually active women increased their bioelectric activity in a neutral position when using the trainer, exerting less effort in retroversion (%-maximal voluntary contraction). Incontinent and menopausal women exhibited slower body-building activation (decreased frequency) with the device, which requires further investigation. Our innovative biofeedback device induced greater recruitment of muscle fibers, is more effective in the neutral pelvic position, and may be effective in training the pelvic floor muscles, even in women with a greater tendency toward pelvic floor dysfunction.
An ophthalmological implant including an imaging optical element, and a haptic with a haptic root. Also, a corresponding method for producing an ophthalmological implant and a characterization system for identifying an ophthalmological implant for example an intraocular lens. The implant includes an unambiguous label and hence an unambiguous and reliable identification option. The label is not able to be mixed-up and is possible with minimal additional technical outlay. The implant includes a rotationally symmetric structural code of identification data of the ophthalmological implant arranged on the haptic root and/or the region of the haptic proximate the haptic root. Also, a method for producing an ophthalmological implant, in which the implant receives, directly during or after the forming, a rotationally symmetric structural code of identification data.
This open-label randomized clinical trial will be conducted in the department of rheumatology, BSMMU. The rheumatoid arthritis patients with moderate to high disease activity at baseline, disease activity score (DAS28ESR\>3.2) will be considered as primary entry criteria for this study. Consecutive sampling method will be applied. The study will be done in 2 phases, duration of each phase 24 weeks. Considering inclusion and exclusion criteria, total 132 patients are randomized into group A and group B following block randomization. Each group will be consisting of 66 patients. In phase 1 Group A will be put on baricitinib 2 mg once daily and Group B will be put on methotrexate 25 mg weekly. The patients who fail to achieve remission or low disease activity by 24 weeks eligible for entry into phase 2 where group A will be put on baricitinib 4 mg and group B will be put on baricitinib 2 mg in combination with methotrexate 10 mg. Follow-up will be done at the 4th, 12th and 24th week in phase 1 and 28th, 36th and 48th week in phase 2. Response to treatment will be evaluated by DAS 28 ESR. At the end of 24th week endpoint for efficacy will be assessed at by DAS 28ESR. Adverse effects will be assessed by history, physical examinations and investigations.

Results will be compared among two groups with a 95% confidence interval and a p-value of \< 0.05. The degrees of statistical significance between groups will be analyzed by unpaired t-test and/or Mann-Whitney U test. Qualitative data in between groups will be analyzed by the chi-square test. Probabilities of associations will be assessed by calculating Spearman´s rank correlation coefficient
Participants with advanced solid tumors with or without Hippo pathway mutations will receive SW-682 tablets administered orally in continuous 28-day cycles. SW-682 dosage and frequency of administration will vary by cohort.
ILUMYA should only be administered by a healthcare provider. Administer ILUMYA subcutaneously. Each prefilled syringe is for single-dose only. Inject the full amount (1 mL), which provides 100 mg of tildrakizumab per syringe. If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regularly scheduled interval.
Disclosed is an applocation of an abstract of a plant endogenetic fungi fermentation product for antagonizing immunodeficiency virus(HIV). Said fungi is isolated from the roots of Orchidaceae medicinal herb Dendrobium nobile, and is EF1(Epulorhiza sp.); EF1s are fluid fermentation cultured to prepare an abstract of the fermentation product. The invention is provided with simplicity of fermentation art, short period of production, and mass industrialization production. The abstract of the fermentation product is obtained easily, and has a remarkable anti-HIV-1 activity, the acting site of which is after reverse transcription and before HIV RNA expression, with a regulation action of HIV-1 gene expression. An adding action is obtained by a combined use of the said fungi fermentation product and anti-HIV drug AZT, indicated by a drug combination test. The abstract of the fungi fermentation product has an important value in the development of novle anti-HIV drugs, and is hopefule to become a novel anti-HIV drug.
BACKGROUND: This study sought to explore the underlying mechanism of miR-21 mediated apoptosis and inflammation in chronic obstructive pulmonary disease (COPD) induced by cigarette smoke (CS).
METHODS: We detected levels and PTEN/Akt/NF-κB axis protein levels in peripheral lung tissues of COPD patients and CS-exposed mice and HBE cells. Western blotting assay was used to determine the expression of cleaved caspase-3. IL-6 and IL-8 protein was detected in cell supernatant from cells by ELISA. HBE cells were transfected with a miR-21 inhibitor, and co-culture with A549.
RESULTS: Increased miR-21 expression, reduced PTEN expression and following activation of Akt in in peripheral lung tissues of COPD patients and CS-exposed mice and HBE cells. Inhibition of miR-21 showed enhanced PTEN levels and reduced the expression of phosphorylated form of Akt and NF-κB. Decreased expression of cleaved caspase-3, IL-6 and IL-8 in A549 cells co cultured with HBE cells transfected with miR-21 inhibitor compared with transfected with miR-21 control inhibitor.
CONCLUSION: MiR-21 contributes to COPD pathogenesis by modulating apoptosis and inflammation through the PTEN/Akt/NF-κB pathway. Targeting miR-21 may increase PTEN expression and inhibit Akt/NF-κB pathway, offering potential diagnostic and therapeutic value in COPD management.
Application of commercially available product with Dressing Application, to be changed weekly following surgical debridement. Patient will practice Offloading. If the ulcer has not closed completely, an additional application of commercially available product will be applied weekly at weeks 2-11.
Arm 2 (termed HCS-only) displayed the HCS on eligible products, crossed referenced via the Health Promotion Board's HCS database (https://www.hpb.gov.sg/food-beverage/healthier-choice-symbol). Out of the 4,177 products available on NUSMart, 311 (7·45%) carried the HCS. This was comprised of 150 foods and 161 beverages.